Conditions: Postmenopausal Osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 140
Healthy volunteers: no

Brief summary:
This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

Detailed description:

Arms:
arm 1: Participants received monthly oral ibandronate (150 milligrams \[mg\]) for 12 months. arm 2: Participants received monthly oral placebo for 12 months.

Interventions: intervention 1: Placebo intervention 2: ibandronate
Intervention descriptions: intervention 1: po monthly for 12 months intervention 2: 150mg po monthly for 12 months

Protocol document: